Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase III single arm pivotal study assessing narsoplimab for hematopoietic stem cell transplant-associated thrombotic microangiopathy (HSCT-TMA)

Next Previous
X
Search
Trial Profile

A Phase III single arm pivotal study assessing narsoplimab for hematopoietic stem cell transplant-associated thrombotic microangiopathy (HSCT-TMA)

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 22 Apr 2022

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Narsoplimab (Primary)
  • Indications Thrombotic microangiopathy
  • Focus Registrational; Therapeutic Use
  • Sponsors Omeros Corporation

    • Most Recent Events

    • 20 Apr 2022 According to an Omeros Corporation media release, manuscript detailing the results of this trial was published online by JCO, the flagship publication of the American Society of Clinical Oncology.
    • 20 Apr 2022 According to an Omeros Corporation media release, data from this trial will be published in an upcoming volume of the Journal of Clinical Oncology (JCO).
    • 10 May 2021 According to an Omeros Corporation media release, an abstract on narsoplimab treatment in adults with high-risk TA-TMA has also been accepted for oral presentation at the 2021 Congress of the European Hematology Association (EHA) in June.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top